The FDA's review of the drug has become a flashpoint in longstanding debates over standards used to evaluate therapies for hard-to-treat conditions. On one side, groups representing Alzheimer's patients and their families say any new therapy — even one of small benefit — warrants approval. B...
From shareholders, patients, governments, non-government organisations, payers and employees we hear many different questions. For this year's Annual Report we have focused on five key questions that lie at the heart of the business. Q A Summary Our markets are changing and we are evolving ...